A Review of Dementia with Lewy Bodies' Impact, Diagnostic Criteria and Treatment

Samuel D. Capouch, Martin Farlow, Jared R. Brosch

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Dementia with Lewy bodies is one of the most common causes of dementia. It is not as common as Alzheimer’s disease; the general public's awareness of the disease is poor in comparison. Its effects on caregivers and patients alike are not well known to the general population. There are currently no FDA-approved medications specifically for the treatment of DLB. Many of the medications that are approved for Alzheimer’s disease are widely used in the treatment of DLB with varying degrees of success. Treatment of DLB is life long and requires a dedicated team of physicians and caregivers to minimize the degree of morbidity and mortality experienced by the patients suffering from the disease as it progresses.

Original languageEnglish (US)
Pages (from-to)249-263
Number of pages15
JournalNeurology and Therapy
Volume7
Issue number2
DOIs
StatePublished - Dec 1 2018

Fingerprint

Lewy Body Disease
Caregivers
Alzheimer Disease
Dementia
Therapeutics
Morbidity
Physicians
Mortality
Population

Keywords

  • Alpha-synuclein
  • Dementia
  • Dementia with Lewy bodies
  • Lewy body dementia

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

A Review of Dementia with Lewy Bodies' Impact, Diagnostic Criteria and Treatment. / Capouch, Samuel D.; Farlow, Martin; Brosch, Jared R.

In: Neurology and Therapy, Vol. 7, No. 2, 01.12.2018, p. 249-263.

Research output: Contribution to journalReview article

Capouch, Samuel D. ; Farlow, Martin ; Brosch, Jared R. / A Review of Dementia with Lewy Bodies' Impact, Diagnostic Criteria and Treatment. In: Neurology and Therapy. 2018 ; Vol. 7, No. 2. pp. 249-263.
@article{78a972799fee4feea65cb79f91d31dba,
title = "A Review of Dementia with Lewy Bodies' Impact, Diagnostic Criteria and Treatment",
abstract = "Dementia with Lewy bodies is one of the most common causes of dementia. It is not as common as Alzheimer’s disease; the general public's awareness of the disease is poor in comparison. Its effects on caregivers and patients alike are not well known to the general population. There are currently no FDA-approved medications specifically for the treatment of DLB. Many of the medications that are approved for Alzheimer’s disease are widely used in the treatment of DLB with varying degrees of success. Treatment of DLB is life long and requires a dedicated team of physicians and caregivers to minimize the degree of morbidity and mortality experienced by the patients suffering from the disease as it progresses.",
keywords = "Alpha-synuclein, Dementia, Dementia with Lewy bodies, Lewy body dementia",
author = "Capouch, {Samuel D.} and Martin Farlow and Brosch, {Jared R.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1007/s40120-018-0104-1",
language = "English (US)",
volume = "7",
pages = "249--263",
journal = "Neurology and Therapy",
issn = "2193-8253",
publisher = "Springer Healthcare",
number = "2",

}

TY - JOUR

T1 - A Review of Dementia with Lewy Bodies' Impact, Diagnostic Criteria and Treatment

AU - Capouch, Samuel D.

AU - Farlow, Martin

AU - Brosch, Jared R.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Dementia with Lewy bodies is one of the most common causes of dementia. It is not as common as Alzheimer’s disease; the general public's awareness of the disease is poor in comparison. Its effects on caregivers and patients alike are not well known to the general population. There are currently no FDA-approved medications specifically for the treatment of DLB. Many of the medications that are approved for Alzheimer’s disease are widely used in the treatment of DLB with varying degrees of success. Treatment of DLB is life long and requires a dedicated team of physicians and caregivers to minimize the degree of morbidity and mortality experienced by the patients suffering from the disease as it progresses.

AB - Dementia with Lewy bodies is one of the most common causes of dementia. It is not as common as Alzheimer’s disease; the general public's awareness of the disease is poor in comparison. Its effects on caregivers and patients alike are not well known to the general population. There are currently no FDA-approved medications specifically for the treatment of DLB. Many of the medications that are approved for Alzheimer’s disease are widely used in the treatment of DLB with varying degrees of success. Treatment of DLB is life long and requires a dedicated team of physicians and caregivers to minimize the degree of morbidity and mortality experienced by the patients suffering from the disease as it progresses.

KW - Alpha-synuclein

KW - Dementia

KW - Dementia with Lewy bodies

KW - Lewy body dementia

UR - http://www.scopus.com/inward/record.url?scp=85058971989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058971989&partnerID=8YFLogxK

U2 - 10.1007/s40120-018-0104-1

DO - 10.1007/s40120-018-0104-1

M3 - Review article

AN - SCOPUS:85058971989

VL - 7

SP - 249

EP - 263

JO - Neurology and Therapy

JF - Neurology and Therapy

SN - 2193-8253

IS - 2

ER -